Given the high economic burden in patients with heart failure with reduced ejection fraction (HFrEF) who have recently experienced worsening HF event(s) in the US, this study intends to assess whether vericiguat is cost effective as an add-on therapy to prior standard-of-care therapies (PSoCT) versus PSoCT alone in the VICTORIA trial population from a US Medicare perspective.

Vericiguat plus PSoCT compared with PSoCT alone resulted in an incremental cost of $82,448 per QALY gained.

Vericiguat plus PSoCT was estimated to result in longer life expectancy and to be cost effective at a willingness-to-pay threshold of $100,000 per QALY gained in the overall VICTORIA intent-to-treat population.